Event and Live Webcast to be Held on December 10th
at 8:15 PM ET in Atlanta
BOSTON--(BUSINESS WIRE)--Dec. 5, 2017--
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to improve the survival and quality of life of cancer patients,
will present clinical data from the Phase 3 DUO study evaluating the
efficacy and safety of duvelisib in patients with relapsed or refractory
chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) at a
Research and Development reception at the American Society of Hematology
(ASH) 2017 Annual Meeting. The event will take place on Sunday, December
10, 2017 in Atlanta.
The event, which follows the oral presentation of the DUO data results
at ASH, will feature a slide presentation and moderated panel discussion
with recognized experts in the treatment of hematologic malignancies,
including CLL/SLL, and a live Q&A session. Speakers will include Ian
Flinn, MD, PhD, Sarah Cannon Research Institute, who will present
results from the Phase 3 DUO study, and Steven Horwitz, MD, Memorial
Sloan Kettering Cancer Center, who will provide an update on duvelisib
for the treatment of Peripheral T-Cell Lymphoma (PTCL). In addition,
Lori Kunkel, MD, Verastem Clinical and Scientific Advisory Board, and
Steven Bloom, Verastem Chief Strategy Officer, will participate in the
discussion panel and Q&A session, which will be moderated by Robert
Forrester, Verastem President and Chief Executive Officer.
The event will take place during the ASH 2017 Annual Meeting and is open
to analysts and institutional investors. Interested parties can access a
live webcast of the event beginning Sunday, December 10, 2017 at 8:15
p.m. ET on the "Presentations" page of the company's website http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-calendar.
A replay of the webcast will be archived on the company's website for 90
days following the event. For more information or to RSVP, please
contact Maeve Conneighton at email@example.com.
Duvelisib is Verastem’s first in class oral dual inhibitor of
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma which is currently
being developed for the treatment of CLL/SLL, peripheral T cell lymphoma
(PTCL), and other hematologic malignancies.
Duvelisib is a first-in-class investigational, dual inhibitor of
phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, two enzymes known
to help support the growth and survival of malignant B-cells and
T-cells. PI3K signaling may lead to the proliferation of malignant
B-cells and is thought to play a role in the formation and maintenance
of the supportive tumor microenvironment.1,2,3 Duvelisib is
currently being evaluated in late- and mid-stage extension trials,
including DUO™, a randomized, Phase 3 monotherapy study in patients with
relapsed or refractory chronic lymphocytic leukemia (CLL)/small
lymphocytic lymphoma (SLL),4 and DYNAMO™, a single-arm, Phase
2 monotherapy study in patients with refractory indolent non-Hodgkin
lymphoma (iNHL).5 Both DUO and DYNAMO achieved their primary
endpoints and Verastem intends to submit a New Drug Application (NDA)
requesting the full approval of duvelisib for the treatment of patients
with relapsed or refractory CLL/SLL, and accelerated approval for the
treatment of patients with relapsed or refractory follicular lymphoma
(FL). Duvelisib is also being developed by Verastem for the treatment of
peripheral T-cell lymphoma (PTCL), and is being investigated in
combination with other agents through investigator-sponsored studies.6 Information
about duvelisib clinical trials can be found on www.clinicaltrials.gov.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to improve outcomes for patients with
cancer. Verastem is currently developing duvelisib, a dual inhibitor of
PI3K-delta and PI3K-gamma, which has successfully met its primary
endpoint in a Phase 2 study in iNHL and a Phase 3 clinical trial in
patients with CLL/SLL. In addition, Verastem is developing the FAK
inhibitor defactinib, which is currently being evaluated in three
separate clinical collaborations in combination with immunotherapeutic
agents for the treatment of several different cancer types, including
pancreatic cancer, ovarian cancer, non-small cell lung cancer, and
mesothelioma. Verastem’s product candidates seek to treat cancer by
modulating the local tumor microenvironment, enhancing anti-tumor
immunity, and reducing cancer stem cells. For more information, please
1 Winkler et al. PI3K-delta and PI3K-gamma inhibition by
IPI-145 abrogates immune responses and suppresses activity in autoimmune
and inflammatory disease models. Chem Biol 2013; 20:1-11.
et al. Cutting Edge: Differential roles for phosphoinositide 3 kinases,
p110-gamma and p110-delta, in lymphocyte chemotaxis and homing. J
3 Schmid et al. Receptor
tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3K,
a single convergent point promoting tumor inflammation and progression.
Cancer Cell 2011;19:715-727.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171205005400/en/
Source: Verastem, Inc.
Brian Sullivan, 781-292-4214